Bristol-Myers Squibb

Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer
Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
bladder cancer
Flag link:
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
drug pricing
regulatory
Celgene
Bristol-Myers Squibb
Teva Pharmaceutical
Amgen
Novartis
Mallinckrodt
AbbVie
US Congress
Flag link:
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Flag link:
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
Endpoints
Bristol-Myers Squibb
ESMO
Opdivo
esophageal cancer
Flag link:
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
Flag link:
FDA approves Onureg as continued treatment for adults in first remission with AML
FDA approves Onureg as continued treatment for adults in first remission with AML
Pharmaceutical Business Review
Bristol-Myers Squibb
Onureg
FDA
AML
Flag link:
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
Fierce Biotech
Jounce Therapeutics
Gilead Sciences
Bristol-Myers Squibb
biobucks
immuno-oncology
Flag link:
ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study
ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eliquis
Xarelto
site-specific bleeding
RWE
ESC
Flag link:
Go or no go? A quiet month ahead for US approval verdicts
Go or no go? A quiet month ahead for US approval verdicts
EP Vantage
FDA
Bristol-Myers Squibb
CC-486
AML
Mallinckrodt
terlipressin
Mesoblast
Ryoncil
Flag link:
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Flag link:
Bristol Myers Squibb's Idhifa Flunks Acute Myeloid Leukemia Trial
Bristol Myers Squibb's Idhifa Flunks Acute Myeloid Leukemia Trial
BioSpace
Bristol-Myers Squibb
clinical trials
enasidenib
acute myeloid leukemia
Flag link:
Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs
Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs
Fierce Biotech
Bristol-Myers Squibb
M&A
Forbius
Opdivo
Flag link:
Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program
Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program
Fierce Biotech
Bristol-Myers Squibb
Dragonfly Therapeutics
IL-12 immunotherapy
DF6002
Flag link:
FDA to decide on TG Therapeutics’ lymphoma drug early next year
FDA to decide on TG Therapeutics’ lymphoma drug early next year
Pharmaforum
TG Therapeutics
FDA
lymphoma
umbralisib
Bristol-Myers Squibb
Roche
Flag link:
Bristol Myers Squibb commits $300 million to combat racial disparities and double number of Black, Latino executives
Bristol Myers Squibb commits $300 million to combat racial disparities and double number of Black, Latino executives
Endpoints
Bristol-Myers Squibb
clinical trials
racial diversity
racial disparity
Flag link:
Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies
Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies
BioSpace
Bristol-Myers Squibb
Opdivo
clinical trials
gastric cancer
esophageal cancer
Flag link:
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Fierce Pharma
WCLC
lung cancer
mesothelioma
Bristol-Myers Squibb
Opdivo
Yervoy
clinical trials
Flag link:
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
BioPharma Dive
Bristol-Myers Squibb
Pfizer
patents
Eliquis
generics
Delaware
Flag link:
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Pharmaforum
Roche
Tecentriq
FDA
melanoma
Bristol-Myers Squibb
Merck
Flag link:
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
Flag link:

Pages